Drug Discovery
ByWhy Is Roche Returning to China for Its Next Antibody-Drug Conjugate Bet?
January 2026 – Strategic Partnerships | China Biopharma | Oncology & ADCs Roche has extended its collaboration with…
Roche Signals Dual Growth Strategy: Price Reform Alignment in the U.S. and Aggressive Expansion Across Oncology and Obesity
January 2026 | Pharma & Policy | Bloomberg Interview Insight Roche is positioning itself for its next growth…
Can Amgen’s Strategic Partnerships Redefine Access and Growth in the GLP‑1 Market?
23 January 2026 Executive Summary Amgen is actively exploring strategic collaborations with telehealth platforms and other access-focused partners…
Could Amgen’s 340B Pricing Practices Face Legal and Market Scrutiny?
23 January 2026 Executive Summary A healthcare advocacy group, Sagebrush, has filed a lawsuit against Amgen Inc., alleging…
Is AstraZeneca Building the Most Diversified Growth Engine in Global Pharma?
Late January–Early February 2026 | Full-Year 2025 Earnings Preview | Oncology, CVRM & Platform Innovation AstraZeneca is expected…
Can Merck Redefine Its Growth Story Beyond Keytruda as the Patent Clock Ticks?
Late January 2026 | Full-Year 2025 Earnings Preview | Oncology, Vaccines & Post-Keytruda Strategy Merck & Co. (known…
